MLICM
XFOR icon

Metropolitan Life Insurance Company (MetLife)’s X4 Pharmaceuticals XFOR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-226
Closed -$7.39K – 2392
2023
Q3 		$7.39K Hold
226
– – ﹤0.01% 2338
2023
Q2 		$13.2K Buy
+226
New +$11.6K ﹤0.01% 2151

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s XFOR Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of X4 Pharmaceuticals (XFOR) in Q4 2023, closing a stake of 226 shares — an estimated $7.39K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in XFOR in Q2 2023 and held it in 2 quarters. The position peaked at $13.2K in Q2 2023. 93 funds tracked by Wall St. Rank hold XFOR as of Q4 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining X4 Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 226 X4 Pharmaceuticals shares in Q4 2023, an estimated $7.39K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s X4 Pharmaceuticals position peaked at $13.2K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.